CD4 antibodies are engineered to bind specifically to the CD4 glycoprotein, which functions as a co-receptor for the T-cell receptor (TCR) and facilitates interactions with MHC class II molecules on antigen-presenting cells. The CD4 protein comprises four immunoglobulin-like domains (D1-D4) and interacts with the β2-domain of MHC II via its D1 domain .
Immunoadhesins: Fusion proteins combining CD4 with immunoglobulin Fc domains (e.g., CD4-IgG1). These enhance plasma half-life and effector functions like antibody-dependent cell-mediated cytotoxicity (ADCC) .
Monoclonal Antibodies: Target-specific epitopes on CD4, such as MAX.16H5 (blocks CD4 interactions with MHC II) or 13B8.2 (antagonizes HIV gp120 binding) .
CD4 antibodies have been explored in:
a. HIV/AIDS Therapy
CD4 immunoadhesins mimic natural CD4 to bind HIV’s gp120 envelope protein, preventing viral entry into host cells. Preclinical studies demonstrate efficacy in blocking infection and inducing cytokine production (e.g., IL-2, IFN-γ) .
b. Autoimmune Diseases
MAX.16H5 shows promise in treating rheumatoid arthritis and lupus by modulating T-cell responses. Phase I/II trials highlight reduced immune activation and antigen-specific tolerance .
c. Graft-Versus-Host Disease (GVHD)
Ex vivo treatment of allogeneic hematopoietic stem cell transplants with MAX.16H5 suppresses GVHD while preserving graft-versus-leukemia (GVL) effects, improving survival rates .
CD4 antibodies act through:
Direct Blocking: Preventing CD4 interactions with MHC II or viral proteins (e.g., gp120) .
Immunomodulation: Inducing tolerance by disrupting T-cell activation signals .
ADCC Activation: Recruiting immune effector cells to eliminate infected or autoreactive cells .
HIV Studies: CD4-IgG1 fusion proteins exhibit 10-fold higher binding affinity to gp120 compared to soluble CD4 .
Autoimmune Models: MAX.16H5 reduces immune responses to tetanus toxoid by 70% in murine models .
GVHD Trials: Allogeneic transplants treated with MAX.16H5 achieve 90% survival in preclinical leukemia models .